Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB3010 in advanced pancreatic cancer
NCT06054984Phase 1Unknown
- Sponsor
- Ruijin Hospital
- Start
- Sep 2021
- Primary completion
- Jun 2024
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GB3010 in pancreatic cancer (PC), sponsored by Ruijin Hospital. Primary endpoints: Incidence of Treatment Related Adverse Events at 2 years and Peak of Peripheral Blood Concentration and Area under the Peripheral Blood concentration versus time curve at 2 years. Status: unknown.
02
Drugs
GB3010
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06054984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054984.